Page 15 - CUA Adv Prostate Ca Drug Access List-MAR-2022

BC

A BC Cancer Compassionate Access Program request must be approved prior to treatment. 1. BC Cancer
1
Restricted funding* Protocol
2
UGUPENZ
Eligibility : [12-21]
1
• Patients with mCRPC who meet the following criteria: 2. BC Cancer
o Chemotherapy-naïve OR received prior chemotherapy containing docetaxel Benefit Drug
o Should have ECOG PS 0-2 List [3-22]
o Should have life expectancy > 3 months
• Patients treated with abiraterone for mCSPC (UGUMCSPABI) are eligible to receive
Not
mCRPC Tablet enzalutamide (UGUPENZ) for mCRPC
specified • Patients can receive either enzalutamide (UGUPENZ) or abiraterone (UGUPABI) in
mCRPC but not sequential use of these agents

1
Exclusions :
• Previously received enzalutamide, apalutamide or darolutamide for nmCRPC
• Previously received enzalutamide or apalutamide for mCSPC

1
Caution :
• Uncontrolled hypertension
Enzalutamide A BC Cancer Compassionate Access Program request must be approved prior to treatment. 1. BC Cancer
1
(Xtandi) Restricted funding* Protocol
2
Astellas UGUNMPENZ
Eligibility : [8-21]
1
• Patients with nmCRPC who meet the following criteria: 2. BC Cancer
o Chemotherapy-naïve Benefit Drug
o No radiologic evidence of metastases (negative bone scan, negative CT of pelvis, List [3-22]
abdomen, chest)
o ECOG PS 0-2
o PSADT ≤ 10 months
Not • Patients with nmCRPC are eligible to receive one of apalutamide (UGUPAPA),
nmCRPC Tablet
specified darolutamide (UGUNMPDAR), or enzalutamide (UGUNMPENZ, UGUPENZ), but not their
sequential use
• Patients who have progressed on enzalutamide in nmCRPC (UGUNMPENZ)
o Are eligible to receive docetaxel (GUPDOC) and/or cabazitaxel in metastatic CRPC
o Are NOT eligible to receive enzalutamide (UGUPENZ) or abiraterone (UGUPABI) in
metastatic CRPC
1
Exclusions :
• mCRPC
• Prior treatment with apalutamide or darolutamide in nmCRPC
• Uncontrolled hypertension (systolic BP > 160 mmHg or diastolic BP > 95 mmHg)
1
A BC Cancer Compassionate Access Program request must be approved prior to treatment. 1. BC Cancer
Restricted funding* Protocol
2
UGUMCSPE
Eligibility : NZ [12-21]
1
Not • Patients with mCSPC who meet the following criteria:
mCSPC Tablet 2. BC Cancer
specified o Chemotherapy-naïve OR received prior chemotherapy containing docetaxel Benefit Drug
o No prior ADT or ADT for < 6 months for mCSPC List [3-22]
o Should have ECOG PS 0-2
o Should have serum potassium > 3.5 mmol/L … continued

Page 8 | © Canadian Urological Association
v.01-MAR-2022